Tamibarotene: Updated Phase II data

Updated data from the open-label, U.S. Phase II STAR-1 trial in 11 relapsed/refractory patients who failed treatment with all-trans retinoic acid (ATRA) and arsenic trioxide showed that 6 mg/m 2 once-...